Marc Lajoie

Marc Lajoie

About

Detail

Co-founder, Chief Executive Officer
Seattle, Washington, United States

Timeline


work
Job
school
Education
flag
Award
auto_stories
Publication

Résumé


Jobs verified_user 0% verified
  • Outpace Bio
    Co-founder, Chief Executive Officer
    Outpace Bio
    Nov 2020 - Current (5 years 8 months)
  • Lyell Immunopharma
    Co-founder, Sr. Director - Protein & Cell Engineering
    Lyell Immunopharma
    Jan 2019 - Nov 2020 (1 year 11 months)
  • GRO Biosciences
    Co-founder, Advisor
    GRO Biosciences
    Aug 2016 - Mar 2025 (8 years 8 months)
  • University of Washington
    Washington Research Foundation Innovation Postdoctoral Fellow; Cancer Research Institute Fellow
    University of Washington
    Sep 2014 - Dec 2018 (4 years 4 months)
    • Developed de novo designed protein switches capable of performing Boolean logic for ultra-specific cell targeting • Developed protein assemblies that package their own genomes and evolve useful properties for targeted delivery of biologics • Developed multiplex gene synthesis capabilities to cheaply produce gene libraries composed of thousands of defined variants
  • Harvard Medical School
    Graduate Student
    Harvard Medical School
    Jan 2009 - Aug 2014 (5 years 8 months)
    • Developed technologies for genome-scale design, synthesis, and editing • Reassigned the genetic code in E. coli and demonstrated as a general mechanism for multivirus resistance, biocontainment, and incorporating unnatural amino acids
  • Outpace Bio
    CEO
    Outpace Bio
Education verified_user 0% verified
  • Harvard University
    Ph.D, Chemical Biology Program
    Harvard University
    Jan 2008 - Dec 2013 (6 years)
    Genetics Department (2009-2014); Mentor: George Church
  • Dartmouth College
    BA, Biophysical Chemistry
    Dartmouth College
    Jan 2004 - Dec 2008 (5 years)
    Chemistry department: major in biophysical chemistry Engineering department: minor in engineering with a concentration in biotechnology
Awards verified_user 0% verified
  • MIT Technology Review
    35 Innovators Under 35
    MIT Technology Review
    Jan 2019
  • C
    Cancer Research Institute Irvington Postdoctoral Fellow
    Cancer Research Institute
    Jan 2016
  • Washington Research Foundation
    Washington Research Foundation Innovation Postdoctoral Fellow
    Washington Research Foundation
    Jan 2015
  • A
    Innovation and technology delegate
    Academy of Achievement
    Jan 2014
  • F
    30 under 30 in Science
    Forbes Magazine
    Jan 2012
  • Department of Defense
    NDSEG fellowship
    Department of Defense
    Jan 2009
Publications verified_user 0% verified
  • N
    An orthogonalized platform for genetic code expansion in both bacteria and eukaryotes
    Nature Chemical Biology Nature Research
    Feb 2017
    In this study, we demonstrate the feasibility of expanding the genetic code of Escherichia coli using its own tryptophanyl–tRNA synthetase and tRNA (TrpRS–tRNATrp) pair. This was made possible by first functionally replacing this endogenous pair with an E. coli–optimized counterpart from Saccharomyces cerevisiae, and then reintroducing the liberated E. coli TrpRS–tRNATrp pair into the resulting strain as a nonsense suppressor, which was then followed by its directed evolution to genetically encode several new unnatural amino acids (UAAs). These engineered TrpRS–tRNATrp variants were also able to drive efficient UAA mutagenesis in mammalian cells. Since bacteria-derived aminoacyl–tRNA synthetase (aaRS)–tRNA pairs are typically orthogonal in
  • N
    Biocontainment of genetically modified organisms by synthetic protein design
    Nature
    Feb 2015
    Genetically modified organisms (GMOs) are increasingly deployed at large scales and in open environments. Genetic biocontainment strategies are needed to prevent unintended proliferation of GMOs in natural ecosystems. Existing biocontainment methods are insufficient because they impose evolutionary pressure on the organism to eject the safeguard by spontaneous mutagenesis or horizontal gene transfer, or because they can be circumvented by environmentally available compounds. Here we computationally redesign essential enzymes in the first organism possessing an altered genetic code (Escherichia coli strain C321.ΔA) to confer metabolic dependence on non-standard amino acids for survival. The resulting GMOs cannot metabolically bypass their bi
  • Science
    Genomically Recoded Organisms Expand Biological Functions
    Science
    Oct 2013
    We describe the construction and characterization of a genomically recoded organism (GRO). We replaced all known UAG stop codons in Escherichia coli MG1655 with synonymous UAA codons, which permitted the deletion of release factor 1 and reassignment of UAG translation function. This GRO exhibited improved properties for incorporation of nonstandard amino acids that expand the chemical diversity of proteins in vivo. The GRO also exhibited increased resistance to T7 bacteriophage, demonstrating that new genetic codes could enable increased viral resistance.
  • Science
    Probing the limits of genetic recoding in essential genes
    Science
    Oct 2013
    Engineering radically altered genetic codes will allow for genomically recoded organisms that have expanded chemical capabilities and are isolated from nature. We have previously reassigned the translation function of the UAG stop codon; however, reassigning sense codons poses a greater challenge because such codons are more prevalent, and their usage regulates gene expression in ways that are difficult to predict. To assess the feasibility of radically altering the genetic code, we selected a panel of 42 highly expressed essential genes for modification. Across 80 Escherichia coli strains, we removed all instances of 13 rare codons from these genes and attempted to shuffle all remaining codons. Our results suggest that the genome-wide remo
  • N
    Natural reassignment of CUU and CUA sense codons to alanine in Ashbya mitochondria
    Nucleic Acids Research
    Sep 2013
    The discovery of diverse codon reassignment events has demonstrated that the canonical genetic code is not universal. Studying coding reassignment at the molecular level is critical for understanding genetic code evolution, and provides clues to genetic code manipulation in synthetic biology. Here we report a novel reassignment event in the mitochondria of Ashbya (Eremothecium) gossypii, a filamentous-growing plant pathogen related to yeast (Saccharomycetaceae). Bioinformatics studies of conserved positions in mitochondrial DNA-encoded proteins suggest that CUU and CUA codons correspond to alanine in A. gossypii, instead of leucine in the standard code or threonine in yeast mitochondria. Reassignment of CUA to Ala was confirmed at the prote
  • PLOS ONE
    Improving Lambda Red Genome Engineering in Escherichia coli via Rational Removal of Endogenous Nucleases
    PLOS ONE
    Sep 2012
    Lambda Red recombineering is a powerful technique for making targeted genetic changes in bacteria. However, many applications are limited by the frequency of recombination. Previous studies have suggested that endogenous nucleases may hinder recombination by degrading the exogenous DNA used for recombineering. In this work, we identify ExoVII as a nuclease which degrades the ends of single-stranded DNA (ssDNA) oligonucleotides and double-stranded DNA (dsDNA) cassettes. Removing this nuclease improves both recombination frequency and the inheritance of mutations at the 3′ ends of ssDNA and dsDNA. Extending this approach, we show that removing a set of five exonucleases (RecJ, ExoI, ExoVII, ExoX, and Lambda Exo) substantially improves the per
  • N
    Manipulating replisome dynamics to enhance lambda Red-mediated multiplex genome engineering
    Nucleic Acids Research
    Aug 2012
    Disrupting the interaction between primase and helicase in Escherichia coli increases Okazaki fragment (OF) length due to less frequent primer synthesis. We exploited this feature to increase the amount of ssDNA at the lagging strand of the replication fork that is available for λ Red-mediated Multiplex Automatable Genome Engineering (MAGE). Supporting this concept, we demonstrate that MAGE enhancements correlate with OF length. Compared with a standard recombineering strain (EcNR2), the strain with the longest OFs displays on average 62% more alleles converted per clone, 239% more clones with 5 or more allele conversions and 38% fewer clones with 0 allele conversions in 1 cycle of co-selection MAGE (CoS-MAGE) with 10 synthetic oligonucleot
  • Science
    Genome-wide Codon Replacement Using Synthetic Oligonucleotides and Engineered Conjugation
    Science
    Jul 2011
    We present genome engineering technologies that are capable of fundamentally reengineering genomes from the nucleotide to the megabase scale. We used multiplex automated genome engineering (MAGE) to site-specifically replace all 314 TAG stop codons with synonymous TAA codons in parallel across 32 Escherichia coli strains. This approach allowed us to measure individual recombination frequencies, confirm viability for each modification, and identify associated phenotypes. We developed hierarchical conjugative assembly genome engineering (CAGE) to merge these sets of codon modifications into genomes with 80 precise changes, which demonstrate that these synonymous codon substitutions can be combined into higher-order strains without synthetic l
  • J
    Tricyclic Compounds Containing Non-enolizable Cyano Enones. A Novel Class of Highly Potent Anti-inflammatory and Cytopro
    J Med Chem
    Mar 2011
    Forty-four novel tricycles containing nonenolizable cyano enones (TCEs) were designed and synthesized on the basis of a semisynthetic pentacyclic triterpenoid, bardoxolone methyl, which is currently being developed in phase II clinical trials for the treatment of severe chronic kidney disease in diabetic patients. Most of the TCEs having two different kinds of nonenolizable cyano enones in rings A and C are highly potent suppressors of induction of inducible nitric oxide synthase stimulated with interferon-γ and are highly potent inducers of the cytoprotective enzymes heme oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Among these compounds, (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthr
  • G
    Lambda Red Recombination in Escherichia coli Occurs Through a Fully Single-Stranded Intermediate
    Genetics
    Nov 2010
    The phage lambda-derived Red recombination system is a powerful tool for making targeted genetic changes in Escherichia coli, providing a simple and versatile method for generating insertion, deletion, and point mutations on chromosomal, plasmid, or BAC targets. However, despite the common use of this system, the detailed mechanism by which lambda Red mediates double-stranded DNA recombination remains uncertain. Current mechanisms posit a recombination intermediate in which both 5′ ends of double-stranded DNA are recessed by λ exonuclease, leaving behind 3′ overhangs. Here, we propose an alternative in which lambda exonuclease entirely degrades one strand, while leaving the other strand intact as single-stranded DNA. This single-stranded in
This is a community-created genome.